bluebird bio Inc (BLUE.OQ)
BLUE.OQ on NASDAQ Stock Exchange Global Select Market
135.52USD
22 Apr 2019
135.52USD
22 Apr 2019
Change (% chg)
-- (--)
-- (--)
Prev Close
$135.52
$135.52
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
192,672
192,672
52-wk High
$199.35
$199.35
52-wk Low
$87.64
$87.64
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -2.90 | December | 23 Apr 2019 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 8 | 8 | 9 | 9 |
| (2) OUTPERFORM | 8 | 8 | 8 | 8 |
| (3) HOLD | 8 | 8 | 7 | 7 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.00 | 2.00 | 1.92 | 1.92 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 17 | 13.78 | 24.82 | 5.00 | 8.70 |
| Quarter Ending Sep-19 | 17 | 16.92 | 48.36 | 5.21 | 18.88 |
| Year Ending Dec-19 | 23 | 60.86 | 137.43 | 8.10 | 82.20 |
| Year Ending Dec-20 | 22 | 193.15 | 443.00 | 80.66 | 339.81 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | 19 | -2.90 | -2.42 | -3.29 | -1.98 |
| Quarter Ending Sep-19 | 19 | -2.96 | -2.18 | -3.42 | -1.88 |
| Year Ending Dec-19 | 23 | -11.71 | -9.19 | -13.48 | -7.92 |
| Year Ending Dec-20 | 22 | -10.50 | -5.13 | -14.00 | -4.95 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-18 | 8.12 | 19.42 | 11.30 | 139.19 |
| Quarter Ending Sep-18 | 7.51 | 11.53 | 4.02 | 53.55 |
| Quarter Ending Jun-18 | 9.64 | 7.85 | 1.79 | 18.58 |
| Quarter Ending Mar-18 | 5.60 | 15.96 | 10.36 | 185.11 |
| Quarter Ending Dec-17 | 7.06 | 4.17 | 2.89 | 40.93 |
| Earnings (per share) | ||||
| Quarter Ending Dec-18 | -2.87 | -2.72 | 0.15 | -5.22 |
| Quarter Ending Sep-18 | -2.87 | -2.73 | 0.14 | -4.88 |
| Quarter Ending Jun-18 | -2.35 | -2.91 | 0.56 | -24.01 |
| Quarter Ending Mar-18 | -2.07 | -2.31 | 0.24 | -11.70 |
| Quarter Ending Dec-17 | -1.70 | -2.52 | 0.82 | -48.14 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 13.78 | 13.78 | 13.78 | 13.35 | 8.70 |
| Quarter Ending Sep-19 | 16.92 | 16.92 | 16.92 | 17.66 | 18.88 |
| Year Ending Dec-19 | 60.86 | 60.86 | 60.34 | 61.88 | 82.20 |
| Year Ending Dec-20 | 193.15 | 193.15 | 192.34 | 208.80 | 339.81 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | -2.90 | -2.90 | -2.92 | -2.93 | -1.98 |
| Quarter Ending Sep-19 | -2.96 | -2.96 | -2.99 | -2.98 | -1.88 |
| Year Ending Dec-19 | -11.71 | -11.71 | -11.72 | -11.86 | -7.92 |
| Year Ending Dec-20 | -10.50 | -10.50 | -10.53 | -10.54 | -4.95 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-19 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-19 | 0 | 1 | 0 | 1 |
| Year Ending Dec-19 | 1 | 0 | 2 | 1 |
| Year Ending Dec-20 | 0 | 0 | 1 | 0 |
| Earnings | ||||
| Quarter Ending Jun-19 | 0 | 0 | 1 | 0 |
| Quarter Ending Sep-19 | 0 | 0 | 1 | 0 |
| Year Ending Dec-19 | 0 | 1 | 3 | 1 |
| Year Ending Dec-20 | 0 | 0 | 2 | 1 |
Earnings vs. 
Estimates- UPDATE 1-EMA panel recommends approval of Bluebird Bio's first gene therapy
- EMA panel recommends approval of Bluebird Bio's first gene therapy
- UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal
- Amgen antibody shows promise in myeloma trial, gets FDA fast track
- UPDATE 1-Amgen antibody shows promise in myeloma trial, gets FDA fast track